The company’s hospital-based products division, Abraxis Pharmaceutical Products, expects to commence marketing ampicillin and sulbactam immediately. The approval is the tenth product approval the company has received this year.
Administered intravenously or intramuscular, ampicillin and sulbactam is indicated for the treatment of several skin and skin structure, intra-abdominal and gynecological infections due to susceptible strains of microorganisms.
With this approval, Abraxis Pharmaceutical Products now offers the complete line of ampicillin and sulbactam products. According to IMS data, annual sales in 2005 of this product exceeded $10.4 million.